Skip to content
Research Article Open access CC BY 4.0

Assessment of the Adminstration of Low Molecular Weight Heparin for Hemodialysis Anticoagulation in Comparison to Standard Unfractionated Heparin

Emad Abdallah, Osama Mosbah, Ghada Khalifa

Journal of Advances in Medicine and Medical Research · pp. 867–874 · Published 10 Jan 2015

10.9734/BJMMR/2015/15365

Abstract

Background and Aim of Study: The use of Low-molecular-weight heparin (LMWH) for hemodialysis anticoagulation has been proposed as effective and safe for hemodialysis (HD) anticoagulation as standard unfractionated heparin (UFH). The aim of our study was to assess the use of LMWH for hemodialysis anticoagulation in comparison to UFH, including hemorrhagic events and clotting of the extracorporeal dialysis circuit and their effect on lipids profile. Methods: This prospective, randomized study conducted on 44 patients (31 males, 13 females; mean age 53.7.9±14.2 years) with end-stage renal disease on regular hemodialysis. The hemodialysis patients were subjected to UFH and followed prospectively for 16 weeks (48 dialyses sessions) and the same patients were subjected to LMWH (enoxaparin sodium; 40 mg) for a further 16 weeks, clotting of the extracorporeal dialysis circuit and hemorrhagic events were evaluated by visual inspection of the air trap, blood lines and dialyzers and the time required for arterio-venous fistula compression. Kt/V was calculated to determine whether UFH or LMWH had any effect on the adequacy of dialysis and lipid profile were measured at the end of each arm of the study to determine whether UFH or LMWH had any effect on the lipid profile levels. Results: The present study showed that, compared with UFH, the effect of LMWH (enoxaparin sodium) on the number of hemorrhagic events (relative risk, 1.3; 95% CI: 0.317 - 5.613; P=1.000) or clotting of the extracorporeal dialysis circuit (relative risk, 0.75; 95% CI: 0.284 - 1.984; P=1.000) was not significant. There was no significant difference in Kt/V between the UFH arm (1.4±0.4) and LMWH (enoxaparin sodium) arm (1.5±1.2; p=0.6). Also there was no significant differences in serum total Cholesterol, LDL, HDL and TGs between the UFH arm and LMWH (enoxaparin sodium arm). Conclusion: LMWH (Enoxaparin sodium) should be considered as effective and safe as unfractionated heparin in hemodialysis anticoagulation. But currently direct costs are about 26% more. So we recommend, the use of UFH for its low cost.

Anticoagulation hemodialysis heparin enoxaparin.

References (20)

  1. 1 Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety [DOI]
  2. 2 Second generation logarithmic estimates of single-pool variable volume Kt/V [DOI]
  3. 3 Low-Molecular-Weight Heparins Compared with Unfractionated Heparin for Treatment of Acute Deep Venous Thrombosis [DOI]
  4. 4 Meta-Analysis: Low-Molecular-Weight Heparin and Bleeding in Patients with Severe Renal Insufficiency [DOI]
  5. 5 Low-Molecular-Weight Heparin Compared with Intravenous Unfractionated Heparin for Treatment of Pulmonary Embolism [DOI]
  6. 6 College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban.
  7. 7 Safety and Efficacy of Low Molecular Weight Heparins for Hemodialysis in Patients with End-Stage Renal Failure [DOI]
  8. 8 Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes [DOI]
  9. 9 Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies [DOI]
  10. 10 Enoxaparin and Bleeding Complications: A Review in Patients with and without Renal Insufficiency [DOI]
  11. 11 Comparison of low-molecular-weight heparin (enoxaparin sodium) and standard unfractionated heparin for haemodialysis anticoagulation [DOI]
  12. 12 Low-molecular-weight heparin in patients with renal insufficiency [DOI]
  13. 13 Pharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in haemodialysis [DOI]
  14. 14 Heparin clearance during continuous veno-venous haemofiltration [DOI]
  15. 15 Attenuation of platelet reactivity by enoxaparin compared with unfractionated heparin in patients undergoing haemodialysis [DOI]
  16. 16 Anticoagulation therapy during haemodialysis: a comparative study between two heparin regimens [DOI]
  17. 17 Effective anticoagulation by a low molecular weight heparin (Fragmin) in hemodialysis with a highly permeable polysulfone membrane.
  18. 18 Profile of low molecular weight tinzaparin sodium for anticoagulation during hemodialysis.
  19. 19 Lipolytic and anticoagulant activities of a low molecular weight fragment of heparin [DOI]
  20. 20 The new heparins [DOI]

Cited by 3

Comparison of Enoxaparin Sodium and Standard Heparin for Hemodialysis Anticoagulation

Samira Tabiban, Khosrow Rahbar, Behshid Ghadrdoost · Nephro-Urology Monthly · 2017

Showing 1 of 3 known citations — external sources report more than can currently be individually listed.

Related research

Article metrics

Real usage data collected on this platform.

89

Page views

0

PDF downloads

27

Outbound clicks

3

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.